Skip to main content

Table 1 Baseline characteristics of patients treated with CHDF

From: Effect of continuous hemodiafiltration using an AN69ST membrane in patients with sepsis

Parameter AN69ST (n = 32) PMMA (n = 17) P value
Male (%) 71.9 88.2 0.1914
Age (years) 71.1 ± 11.4 74.7 ± 9.4 0.1123
Height (cm) 159.8 ± 8.9 160.7 ± 9.2 0.7845
BMI 22.4 ± 4.7 21.6 ± 3.8 0.4371
Cause of sepsis
 Peritonitis (%) 46.9 64.7 0.2339
 UTI (%) 6.3 11.8 0.5022
 Pneumoniae (%) 15.6 11.8 0.7132
Infection bacteria
 Gram-positive coccus (%) 40.6 41.2 0.9702
 Gram-negative rod (%) 34.4 47.1 0.3857
 Unknown (%) 31.3 23.5 0.5691
Past history
 Diabetes (%) 21.9 23.5 0.8949
 Hypertension (%) 53.1 35.3 0.2339
 Maintenance dialysis (%) 12.5 29.4 0.1456
Ventilator (%) 84.4 94.1 0.3220
Surgical treatment (%) 50.0 76.5 0.0727
SBP (mmHg) 105.2 ± 26.8 107.9 ± 21.7 0.4945
DBP (mmHg) 54.3 ± 13.2 57.6 ± 15.7 0.5012
MBP (mmHg) 71.3 ± 15.9 74.3 ± 16.6 0.5777
HR (bpm) 99.1 ± 22.0 99.8 ± 17.2 0.9828
BT (°C) 37.3 ± 1.0 36.9 ± 1.1 0.0740
CAI 38.5 ± 27.3 28.4 ± 19.2 0.1689
 DOA (μg/kg/min) 0.00 ± 0.00 0.55 ± 2.28 0.1573
 DOB (μg/kg/min) 0.89 ± 2.00 0.55 ± 2.28 0.1918
 NA (μg/kg/min) 0.38 ± 0.26 0.27 ± 0.19 0.1472
WBC (1000/μL) 15.4 ± 9.5 11.8 ± 11.0 0.1035
Hb (g/dL) 10.6 ± 2.1 10.3 ± 1.4 0.4749
Plt (10,000/μL) 14.5 ± 10.8 13.6 ± 7.4 0.8091
ALB (g/dL) 2.0 ± 0.5 1.9 ± 0.5 0.6591
AST (IU/L) 310.1 ± 754.4 285.7 ± 999.8 0.2610
ALT (IU/L) 172.2 ± 440.3 118.2 ± 388.2 0.1753
UN (mg/dL) 57.2 ± 24.3 48.0 ± 26.1 0.1252
Cr (mg/dL) 3.6 ± 2.2 3.9 ± 3.6 0.4067
eGFR (ml/min/1.7 m2) 19.0 ± 12.9 25.8 ± 19.0 0.4127
Na (mEq/L) 138.2 ± 4.1 137.8 ± 6.3 0.2291
K (mEq/L) 4.5 ± 1.0 4.3 ± 0.8 0.3714
cCa (mg/dL) 9.4 ± 0.9 9.4 ± 0.9 0.8058
P (mg/dL) 4.6 ± 1.7 4.7 ± 1.9 0.8148
Mg (mg/dL) 2.0 ± 0.5 1.8 ± 0.3 0.3516
CRP (mg/dL) 20.4 ± 12.5 14.8 ± 12.2 0.0991
HCO3 (mEq/L) 16.9 ± 5.6 17.0 ± 4.3 0.8500
Lactate (mg/dL) 40.4 ± 32.3 23.9 ± 15.3 0.0928
APACHE 2 32.1 ± 7.0 32.5 ± 4.8 0.8086
APACHE2 without kidney 29.3 ± 7.1 30.2 ± 4.9 0.7120
SOFA 13.1 ± 2.7 11.9 ± 2.7 0.0807
SOFA without kidney 10.4 ± 2.3 9.5 ± 2.8 0.4709
PMX (%) 25.0 58.8 0.0194*
CRRT (days) 4.4 ± 2.9 5.3 ± 4.9 0.8970
Death at 28 days (%) 43.8 35.3 0.1625
Cr at 28 days (mg/dL) 1.4 ± 1.3 (n = 14) 2.5 ± 1.9 (n = 9) 0.0777
  1. CHDF continuous hemodiafiltration, AN polyacrylonitrile, PMMA polymethyl methacrylate, BMI body-mass index, UTI urinary tract infection, SBP systolic blood pressure, DBP diastolic blood pressure, MBP mean blood pressure, HR heart rate, BT body temperature, CAI catecholamine index, DOA dopamine, DOB dobutamine, NA noradrenalin, WBC white blood cells, Hb hemoglobin, Plt platelet, ALB albumin, AST aspartate aminotransferase, ALT alanine aminotransferase, eGFR estimated glomerular filtration rate, Na sodium, K potassium, cCa corrected calcium, P phosphate, Mg magnesium, CRP C-reactive protein, HCO 3 bicarbonate, APACHE 2 Acute Physiology and Chronic Health Evaluation II score, SOFA sequential organ failure assessment score, PMX polymyxin B-immobilized fiber column hemoperfusion, CRRT continuous renal replacement therapy
  2. *p < 0.05